13 May Parexel
Parexel is a global clinical research organization (CRO) with a focus on community, providing the full range of Phase I to IV clinical development services to help life-saving treatments reach patients faster. We advance cell and gene therapy trials by focusing on empirical data, lived experience, and pragmatic innovation to accelerate clinical development. With comprehensive insights from former regulators and experienced operational delivery units from around the world, we help sponsors navigate new and evolving regulatory and manufacturing challenges, operational complexities, and obstacles to market and patient access. Leveraging the breadth of our clinical, regulatory and therapeutic expertise, our team of more than 21,000 clinical research professionals works in partnership with biopharmaceutical leaders, emerging innovators and study sites to design and deliver cutting edge clinical trials that differentiate in time and space. We believe that increasing access and participation to advanced therapy clinical studies should be a care option for anyone, anywhere. Our industry knowledge and record of 40 years of developing novel therapies gives us the opportunity to proactively address healthcare’s most complex diseases, while our innovation efforts offer data-driven solutions to make each phase of the clinical trial process more efficient while decreasing sponsor spend. Parexel works With HeartTM so that every trial can make a difference. This approach continues to work for us, with Parexel being the recipient of the 2024 and 2023 Society for Clinical Research Sites (SCRS) Eagle Award for advancing the clinical research profession through strong site partnerships and named “Top CRO to Work With” by investigative sites worldwide in the 2023 WCG CenterWatch Global Site Relationship Benchmark Survey.
